Kaleido_rgb_300dpi.jpg
Kaleido Biosciences to Present at Upcoming September Investor Conferences
September 09, 2020 07:00 ET | Kaleido Biosciences
LEXINGTON, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced that Michael Bonney, Executive Chair, will participate in the following upcoming...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Announces Presentation of Data for Microbiome Metabolic Therapy KB174 for Hepatic Encephalopathy at The Digital International Liver Congress™ (EASL)
August 27, 2020 07:00 ET | Kaleido Biosciences
LEXINGTON, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO) today announced that data from Microbiome Metabolic Therapy (MMT™) candidate KB174 for hepatic...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences to Present at the Canaccord Genuity 40th Annual Growth Conference
August 05, 2020 08:00 ET | Kaleido Biosciences
LEXINGTON, Mass., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 04, 2020 07:35 ET | Kaleido Biosciences
- COVID-19 Clinical Development Program Topline Data Readout of Multi-Center Study Expected in Q4 2020 - - Plan to Initiate New Clinical Study in Ulcerative Colitis in Q3 2020 -  LEXINGTON, Mass.,...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Initiates Controlled Clinical Study with Massachusetts General Hospital of Microbiome Metabolic Therapy KB109 in Outpatients with Mild-to-Moderate COVID-19
July 23, 2020 07:00 ET | Kaleido Biosciences
- Second Study Launched in Kaleido’s COVID-19 Clinical Development Program for this Rapidly Growing Patient Population - LEXINGTON, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences,...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Announces CEO Leadership Transition
June 16, 2020 16:45 ET | Kaleido Biosciences
- Alison Lawton to step down as President and Chief Executive Officer to attend to a family health matter - The Board of Directors has established an Office of the CEO to manage the company through...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Announces 2020 Annual Meeting of Stockholders to be Held as Virtual Meeting
June 08, 2020 08:30 ET | Kaleido Biosciences
LEXINGTON, Mass., June 08, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences to Present During the Goldman Sachs 41st Annual Global Healthcare Conference
June 04, 2020 08:30 ET | Kaleido Biosciences
LEXINGTON, Mass., June 04, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Announces Pricing of Public Offering of Common Stock
June 01, 2020 21:30 ET | Kaleido Biosciences
LEXINGTON, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to...
Kaleido_rgb_300dpi.jpg
Kaleido Biosciences Announces Proposed Public Offering of Common Stock
June 01, 2020 16:17 ET | Kaleido Biosciences
LEXINGTON, Mass., June 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to...